BioVentrix Selected to Present at Prestigious EuroPCR Meeting
(Thomson Reuters ONE) -
PARIS--(Marketwire - May 14, 2012) - BioVentrix, the developer of minimally
invasive therapies for the treatment of heart failure, was selected to present
at EuroPCR, the annual meeting of the European Association for Percutaneous
Cardiovascular Interventions, being held in Paris, May 15-17, 2012.
The Company recently reported six-month follow up data from its first-in-man
(FIM) trial for proof-of-concept of its LV volume reduction technology. The
trial took place in an open surgical setting, and data showed excellent results
in heart failure patients who were symptomatic entering the trial, even while on
optimal conventional therapy. Based on these positive surgical outcomes,
BioVentrix is rapidly developing a transcatheter product to achieve the same
results with a sternal sparing technique.
BioVentrix's chief medical officer, Lon S. Annest, M.D., MBA, will present the
FIM clinical results and the company's next generation sternal sparing product
for TransCatheter Ventricular Restoration (TCVR). The presentation will take
place during the "Cardiovascular Innovation Pipeline -- Heart Failure and
Structural Heart Disease" session, to be held the morning of May 16th in the
Palais des Congrès, room 351.
Dr. Annest will highlight the company's progress towards developing a closed
chest, off pump transcatheter hybrid therapy for patients with ischemic
cardiomyopathy delivered by a combined surgical and cardiology team. Patients
with dilated ventricles having akinetic or dyskinetic scar tissue resulting from
a previous myocardial infarction (heart attack) may benefit from minimally
invasive scar exclusion. Typically, these patients may be too ill or too fragile
to tolerate traditional surgical interventions, or they may no longer respond to
standard medical and cardiac rhythm therapy.
"We are honored to be presenting the early clinical results with our plication
technology and key features of the forthcoming transcatheter product, which is
based on the same proven concept," said Ken Miller, president and chief
executive officer of BioVentrix. "We believe this innovative approach will
significantly expand treatment options for patients with ischemic
cardiomyopathy, thereby eliminating the need to open the chest in this very sick
group of patients."
Heart failure in Europe is more common than most cancers(1). Approximately 14
million people in Europe currently suffer from heart failure and this number is
expected to increase to 30 million by the year 2020, according to the Study
Group on Heart Failure Awareness and Perception in Europe (SHAPE). In addition,
over 3.6 million new cases are reported each year and admission to hospitals
with heart failure has more than doubled in the last 20 years.
About BioVentrix
BioVentrix is a privately held medical device company headquartered in San
Ramon, Calif. U.S.A. Its mission is to improve and expand on the treatment of
heart failure, primarily through the development of less invasive, catheter-
based approaches. The company's proprietary systems offers a less invasive,
accelerated recovery treatment that improves cardiac function by restoring the
geometry and resulting function of the left ventricle, thereby improving a
patient's quality of life. The company's clinical investigators include some of
the world's leading surgeons and cardiologists. The BioVentrix system is an
investigational device pending CE Mark. For more information, please visit:
http://bioventrix.com.
(1) Stewart S et al. More malignant than cancer? Five year survival following a
first admission for heart failure. The European Journal of Heart Failure
2001; 3:315-322.
Contact Information
Media Contact:
Amy Cook
925.552.7893
amycook(at)amcpublicrelations.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioVentrix via Thomson Reuters ONE
[HUG#1610765]
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 146071
Anzahl Zeichen: 4696
contact information:
Town:
San Ramon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioVentrix Selected to Present at Prestigious EuroPCR Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
BioVentrix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
